I’d squirt the spray into my nose, where it’d drip to the back of my throat. The taste was potent: The office kept a dish of meltaway mints next the chair. And then, for maybe minutes, I'd wait for ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Bryan’s Mental Health Services is now offering an innovative drug called Spravato. It was approved in 2019 to treat depression, but some medical professionals say the treatment flew under the ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged more than 46% to a record low on Monday as the ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

While its effectiveness is still being researched, clinical therapists across the country and here at Bryan Medical say it’s mostly beneficial for treatment-resistant depression patients.

Of the 8.9 million people in the United States with depression, it’s estimated that 30% have treatment resistant depression, according to a 2021 study in the National Institutes of Health.